|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Blockade with [d-Phe<sup>6</sup>,Leu-NHEt<sup>13</sup>,des-Met<sup>14</sup>]bombesin(6-14) significantly reduced the average uptake of [<sup>68</sup>Ga]Ga-ProBOMB1 in tumors by 62%.
|
30775647 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bombesin (Bn) receptors have shown great promise for tumor targeting due to their increased expression in a variety of human cancers, including prostate, breast, small cell lung, and pancreatic cells.
|
31295552 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In nude mice, MDA-MB-231 tumor uptake profiles were slightly different; the BN peptide with Ahx spacer and linked to DOTA through cyclen exhibited higher tumor uptake (2.32% ID/g at 1 h post-injection) than other radiolabeled BN peptides investigated in this study.
|
31502101 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
At 47 days after surgery, lymph nodes, liver, and bone metastasis appeared, and tumor markers such as ProGRP and NSE were elevated.
|
30313107 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo behaviour of the radiopeptides was evaluated in GRP receptor positive tumor bearing mice.
|
28088445 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gastrin-releasing peptide is a neuropeptide linked to tumor aggressiveness, acting as an autocrine tumor growth factor by binding to its receptor, gastrin-releasing peptide receptor, expressed by many tumors.
|
28351312 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gastrin-releasing peptide receptors (GRP-Rs, also known as bombesin 2 receptors) are overexpressed in a variety of human cancers, including prostate cancer, and therefore they represent a promising target for in vivo imaging of tumors using positron emission tomography (PET).
|
27863916 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
|
28792505 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In Vitro Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells.
|
28186846 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Impact of dianionic and dicationic linkers on tumor uptake and biodistribution of [<sup>64</sup> Cu]Cu/NOTA peptide-based gastrin-releasing peptide receptors antagonists.
|
28129446 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, novel ligands which interact with other receptors (GLP-1, bombesin, cholecystokinin, gastric inhibitory polpeptide, integrin, chemokines) are described, which show promise in the imaging of both NETs and other tumors.
|
27875420 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We herein compare the impact of the two methods on the bioavailability and localization of <sup>177</sup>Lu-DOTA-PEG<sub>4</sub>-[Nle<sup>14</sup>]BBN(7-14) analogs in GRPR-positive tumors in mice.
|
28636973 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Distribution of serum levels of ProGRP, NSE and ProGRP mRNA differed significantly according to tumor size, disease stage and distant metastasis (all P < 0.05), and no association was found between them and gender or age (both P > 0.05).
|
26886220 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The new (99m)Tc-labeled biomolecule was stable in vitro, showed high affinity for the human GRP receptor expressed in PC3 cells and the rate of internalization was found to be time-dependent tissue distribution of the radiopeptide was evaluated in normal mice and in prostate cancer experimental models and significant radioactivity uptake was observed in the pancreas of normal mice as well as in PC3 tumors.
|
24035515 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The circulating proGRP could serve as a valuable tumor marker for small-cell lung cancers, and the plasma level of proGRP is more stable compared with that of serum proGRP.
|
23222852 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, PTEN overexpression decreased GRP-mediated migration and angiogenesis; a novel role for this, otherwise, understated tumor suppressor in neuroblastoma.
|
24039782 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Receptor assays demonstrated high-affinity binding sites for BN/GRP in both tumor lines.
|
22926257 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The GRPR, localized and expressed in extremely high density in a subgroup of vessels, may function as target for antiangiogenic tumor therapy or angiodestructive targeted radiotherapy with radiolabeled bombesin analogs alone, or preferably together with VEGFR targeted therapy.
|
21605611 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Radiolabeled GRPR-targeting analogs of bombesin (BN) have successfully been introduced as potential tracers for visualization and treatment of GRPR-overexpressing tumors.
|
19876914 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gastrin-releasing peptide (GRP) plays an important role in regulating tumor growth and migration.
|
20596631 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The advantages of the RGD-BBN radiotracers over the corresponding BBN analogues are obvious for imaging MDA-MB-435 (GRPR(-)/integrin alpha(v)beta(3)(+)) tumor.
|
20540537 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These data indicate that GRP upregulation of ICAM-1 via FAK promotes tumor cell motility and attachment to the extracellular matrix.
|
16920698 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Yet by studying human tissues, we have recently shown that bombesin and its mammalian homologue gastrin-releasing peptide act as morphogens, promoting tumor differentiation when aberrantly upregulated in colon cancer.
|
15528253 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All tumors expressed mRNA for subtype 1 bombesin/GRP receptor, but MiaPaCa-2, and in one experiment, SW-1990 tumors did not show binding sites for bombesin.
|
16163060 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This conjugate binds strongly to receptors for bombesin/GRP and can be targeted to tumors that express these receptors.
|
15788692 |
2005 |